AI that learns from the lab: a new blueprint for antibiotic alternatives under resistance pressure

Antimicrobial resistance is quietly becoming one of the defining medical crises of our time, and the pipeline of new antibiotics is not keeping pace. Now, an international team of researchers from Mexico, Chile and Germany has published a Perspective in Frontiers in Drug Discovery that argues the problem is not a lack of sophisticated algorithms but a structural mismatch in how artificial intelligence is organised for drug discovery. Their proposal, released on 17 July 2026, reframes the search for antimicrobial peptides as a continuous, self-correcting loop between computer and laboratory rather than a one-off computational exercise.

Therapeutic peptides, short chains of amino acids that can punch holes in bacterial membranes or disrupt essential microbial processes, have long been touted as alternatives to conventional antibiotics. They are structurally diverse, chemically tunable and often engage multiple microbial targets at once, which makes it harder for pathogens to develop resistance through a single mutation. Yet the authors are blunt about a widespread misconception: peptides do not inherently prevent resistance. Bacteria evolve proteases that degrade them, efflux pumps that expel them, and membrane modifications that reduce susceptibility, meaning any discovery strategy that ignores these adaptive mechanisms is designing for a battlefield that has already shifted.

The core critique centres on fragmentation. Current AI-driven workflows typically consist of isolated tools: a classifier that labels sequences as antimicrobial or not, a generative model that proposes novel sequences, and an explainability layer bolted on afterwards. Each component may perform well in benchmarks, but they rarely exchange information coherently. A model that achieves high accuracy on a static test set provides little translational value if it cannot tell researchers why a particular sequence is predicted to be active, how confident it is, or what happens when a pathogen evolves a new resistance mechanism mid-campaign. The result is a discovery process that is technically impressive but operationally brittle.

Interpretability is a particular sore point. Deep learning architectures dominate modern peptide prediction, but they function largely as black boxes. Post hoc explainability methods such as SHAP and LIME can attribute importance to individual features, yet these attributions are sensitive to model architecture, training conditions and input perturbations, and they rarely reveal stable, global patterns of antimicrobial activity. Compounding the problem, many pipelines rely on embedding-based representations derived from protein language models, which improve predictive performance but introduce an abstraction layer that decouples model outputs from interpretable biochemical features. Even when attribution maps are produced, translating them into actionable design decisions becomes difficult because the underlying feature space lacks direct biological meaning.

Compounding the interpretability deficit is the problem of static pipelines. Models are typically trained on in vitro datasets and deployed as fixed predictors, with limited incorporation of experimental feedback for iterative refinement. This is particularly problematic in peptide discovery, where discrepancies between in vitro and in vivo performance are common. A peptide predicted to be highly active may fail under physiological conditions because of degradation, serum binding, immune interactions or altered pharmacokinetics. The authors note that this decoupling is not only methodological but also organisational: computational and experimental groups often operate under different constraints, timescales and throughput capacities, with AI systems generating millions of candidates while only a small fraction can realistically be synthesised and tested.

To address these limitations, the researchers propose three interdependent pillars. The first is explainable and uncertainty-aware predictive modelling, which combines local attribution methods with global interpretability strategies and integrates uncertainty quantification techniques such as deep ensembles, Bayesian neural networks and conformal prediction. The second is conditional and rule-aware generative peptide design, which embeds biological constraints directly into the generative process rather than applying them as post hoc filters. The third is orchestrated modular systems governed by design–test–learn principles, in which predictive, generative and interpretability-oriented modules interact iteratively, allowing experimental observations to propagate systematically across the entire discovery process.

Uncertainty awareness deserves particular attention. Antimicrobial peptide datasets are often sparse and biased, especially for resistant phenotypes, making point predictions unreliable under distributional shift. Conformal prediction offers distribution-free confidence guarantees that are particularly valuable in low-data settings, while ensemble-based approaches can identify regions of elevated uncertainty and support candidate ranking when the model encounters sequences unlike anything in its training data. Integrated within active learning frameworks, these estimates can prioritise sequences expected to maximise experimental information gain, transforming candidate selection from a simple ranking exercise into a principled decision-making problem under limited experimental budgets.

To demonstrate these concepts in practice, the team presented a worked example integrating interpretable prediction, uncertainty-aware prioritisation, rule extraction and adaptive model updating. They curated approximately 86,000 peptides from the Peptipedia v2.0 database, removed non-canonical sequences, excluded peptides outside the range of 5 to 60 amino acids, and reduced redundancy through MMseqs2 clustering at 80 percent sequence identity, yielding roughly 47,000 non-redundant peptides. For each sequence, a panel of 41 descriptors was calculated, encompassing amino acid composition, physicochemical properties, sequence complexity, entropy-related measures and structural propensity estimates. An ensemble of ten predictive models, trained under distance-aware data partitioning to better approximate prospective screening scenarios, achieved an overall Matthews correlation coefficient of 0.65 on a held-out evaluation set of approximately 14,000 peptides.

Global SHAP analysis applied to this ensemble revealed that descriptors associated with amino acid composition, charge distribution, physicochemical balance and sequence complexity emerged among the most influential variables, consistent with established mechanistic characteristics of membrane-active antimicrobial peptides. These explanatory signals were then converted into explicit decision rules using surrogate modelling approaches, generating twelve human-readable criteria that can support candidate selection and optimisation. Prediction uncertainty was estimated through ensemble variability and incorporated directly into the prioritisation process, distinguishing between sequences suitable for immediate experimental validation and candidates that may require additional evidence before prioritisation. Application of this multi-criteria strategy to an external screening pool of approximately 16,000 candidate peptides resulted in the prioritisation of 606 sequences for further evaluation.

The authors are careful to note the limitations of this demonstrative application. Extensive hyperparameter optimisation, large-scale benchmarking and exhaustive comparative evaluation were intentionally omitted, and the implementation does not include generative modelling components, explicit modelling of resistance evolution, active learning-based experimental design or feedback derived from wet-laboratory validation. Nevertheless, the example illustrates how complementary sources of information can be transformed into actionable decision support throughout the discovery process. Looking forward, the researchers suggest that advances in active learning, foundation models, autonomous experimentation and scientific agents may further accelerate the development of closed-loop discovery ecosystems. Ultimately, they argue, the impact of artificial intelligence on antimicrobial peptide development will depend not only on predictive performance but on the ability to continuously integrate prediction, experimentation, interpretation and learning within a unified and evolving discovery framework, one capable of adapting as fast as the pathogens it is designed to defeat.

Subject of Research: Toward explainable and adaptive artificial intelligence systems for antimicrobial peptide discovery under resistance pressure

Article Title: Toward explainable and adaptive artificial intelligence systems for antimicrobial peptide discovery under resistance pressure

Article References: Islas-Ávila, A. L., García-Vinuesa, J., Soto-García, N., Soto-García, M., Gutiérrez-Cárdenas, B., Inostroza-Munoz, A., Davari, M. D., Murgas, L., Uribe-Paredes, R., Martínez-Rebollar, A., Sepulveda-Yañez, J., & Medina-Ortiz, D. (2026). Toward explainable and adaptive artificial intelligence systems for antimicrobial peptide discovery under resistance pressure. Frontiers in Drug Discovery, 6, Article 1820604. https://doi.org/10.3389/fddsv.2026.1820604

Image Credits: AI Generated

DOI: 10.3389/fddsv.2026.1820604

Keywords: antimicrobial resistance, antimicrobial peptides, explainable AI, uncertainty quantification, generative design, design–test–learn, machine learning, drug discovery, SHAP, conformal prediction, Toward, explainable